1. 主要终点:Risankizumab 组与安慰剂组相比,至发生首次哮喘恶化的中位时间更短,为 40 天,而安慰剂组的首次哮喘恶化时间为86天(比值比1.46;95%CI 1.05-2.04;P=0.03)。 2. 亚组分析结果 (1)Risankizumab组与安慰剂组相比,首次哮喘恶化的风险在血嗜酸性粒细胞计数较高的患者(EOS≥200细胞/立方毫米)和体...
参考文献：Andrew B. Lassman et, al. Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. Neuro-oncology, 25(2), 339-350, 2023.注：本文仅为对原文的摘录和翻译，不能完全反应原文信息，如有需要请参考原文。本文所涉及的药物处于研究阶段，...
PD-1 Antibody (Tislelizumab) Combined With VEGFR 1/2/3 Inhibitor (Fruquintinib) for ARID1A-mutated Metastatic pMMR/MSS Colorectal Cancer: an Open-label, Multi-center, Phase II Clinical Trial This is an open-label phase II study, with the aim of investigating the efficacy and safety of...
[1] Locke FL, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol 2019; 20(1):31-42. ...
Note: You're limited to 60 minutes of play in the trial version. Download Zuma Deluxe Latest Version Screenshots Top Downloads OperaOpera 117.0 Build 5408.142 (64-bit) PC RepairPC Repair Tool 2025 PhotoshopAdobe Photoshop CC 2025 26.4.1 (64-bit) OKXOKX - Buy Bitcoin or Ethereum iTop ...
Request a free trial If your organization has a subscription, there are several access options, even while working remotely: Working within your organization’s network Login with username/password or try to access via your institution Persisted access using your organization’s identifier stored...
We conducted a randomized, controlled, multicenter, phase 2 trial in 3 centers from China (NCT04830267). Patients with R/M-NPC, without prior exposure to immunotherapy, who presented with ≥2 lesions, and at least 1 measurable lesion were randomized 1:1 to either Cam alone or Cam plus MDT...
teplizumab的BLA,基于TrialNet开展的TN-10研究(“At-Risk”,NCT01030861)的临床数据。该研究评估了teplizumab用于高危群体预防或延缓发生临床1型糖尿病(T1D)的疗效和安全性。结果显示,与安慰剂相比,单个为期2周(14天)疗程的teplizumab治疗显著推迟了高危儿童和成人临床T1D的发病和诊断时间,T1D发病率降低50%,发...
teplizumab的BLA,基于TrialNet开展的“At-Risk”研究的临床数据。该研究评估了teplizumab用于高危群体预防或延缓发生临床1型糖尿病(T1D)的疗效和安全性。结果显示,与安慰剂相比,单个为期2周(14天)疗程的teplizumab治疗显著推迟了高危儿童和成人临床T1D的发病和诊断时间,T1D发病率降低50%,发病中位时间推迟至少2...
6、Sherry N, Hagopian W, Ludvigsson J, et al. Teplizumab for treatment of type 1 diabetes ( Protégé study) : 1-year results from a randomised,placebo-controlled trial[J] . Lancet, 2011, 378( 9790) : 487-497